Apollomics, LaunXP enter development, commercial agreement for Vebreltinib

• Apollomics (NASDAQ:APLM) and LaunXP International, an affiliate of LaunXP Biomedical, announced that the parties have entered into an agreement for the development and commercialization in Asia of vebreltinib, Apollomics' proprietary c-Met inhibitor, in combination with an EGFR inhibitor or the treatment of NSCLC.